uniQure Option Alert: Oct 17 $32 Calls at the Bid: 342 vs 3391 OI; Earnings 11/4 Before Open [est] 

uniQure Option Alert: Oct 17 $32 Calls at the Bid: 342 @ $24.0 vs 3391 OI; Earnings 11/4 Before Open [est] Ref=$56.0472

uniQure Option Alert: Apr 17 $60 Calls at the Bid: 1000 vs 293 OI; Earnings 11/4 Before Open [est] 

uniQure Option Alert: Apr 17 $60 Calls at the Bid: 1000 @ $13.1 vs 293 OI; Earnings 11/4 Before Open [est] Ref=$54.3817

uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Broadcom, Lululemon, Opendoor, Docusign And Neonode: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

BABA

INTC

OPEN

QURE

TSLA

Las acciones estadounidenses retrocedieron el miércoles, con el Nasdaq perdiendo más de 75 puntos, o un 0,3%, para cerrar en 22.497,85. El Dow Jones disminuyó un 0,37% hasta 46.121,28, mientras que el S&amp;P 500 bajó un 0,3% hasta 6.637,97.

Alibaba, Intel, Uniqure, Tesla y Opendoor: 5 acciones que están en el radar de los inversores

uniQure NV

Press Releases

uniQure to Announce Second Quarter 2025 Financial Results

Earnings

Management

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Health Care

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Opinion

Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

Financing

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

uniQure Announces $200 Million Proposed Public Offering

Penny Stocks

Small Cap

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

uniQure Announces Pricing of Upsized $300 Million Public Offering

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

AVAI

EDIT

HCWB

HTGC

SLDB

VCYT

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Veracyte

Viking Therapeutics

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
09:36 AMOct 06, 2025	CALL	$32.00	Oct 17, 2025	9	0	342	0	3391	TRADE	BEARISH
02:55 PMOct 02, 2025	CALL	$60.00	Apr 17, 2026	191	1036	1000	354	293	TRADE	NEUTRAL

Comments

uniQure

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL